Tag: Biosimilars
-
All In on Biosim AI with Simulations Plus: A TD Cowen Insights Discussion
Introduction: A New Frontier in Biosim AI The latest TD Cowen Insights episode dives into the convergence of biology and artificial intelligence, spotlighting how biosimulation experts are reshaping the development of biosimilars. With Simulations Plus at the helm, the discussion unpacks how AI-powered simulations can streamline drug development, improve predictability, and reduce costs. This episode…
-
Mabwell’s Adalimumab Biosimilar Gains Marketing Approval in Indonesia
Overview: Mabwell’s Adalimumab Biosimilar Approved in Indonesia In a significant milestone for global biopharmaceutical access, Mabwell announced that its Adalimumab Injection 9MW0113—marketed as JUNMAIKANG in China—has received marketing approval in Indonesia. The decision marks the company’s first major regulatory clearance in Southeast Asia for a biosimilar of adalimumab, a leading anti-TNF therapy used to treat…
-
All In on Biosim AI with Simulations Plus: TD Cowen Insight
Overview: Biosim AI Takes the Stage The latest TD Cowen Insights episode dives into the accelerating role of biosim AI, a fusion of artificial intelligence with biosimilar development and analysis. Hosted conversations with leading analysts and industry voices reveal how AI-driven simulations, pharmacokinetic modeling, and real-world data are reshaping strategies for creating safe, effective biosimilars…
-
Mabwell Adalimumab Biosimilar Approved in Indonesia
Indonesia Grants Marketing Approval for Mabwell’s Adalimumab Biosimilar In a move that could broaden access to biologic therapies for autoimmune conditions, Mabwell, a Shanghai-based biopharmaceutical company, announced that its Adalimumab Injection 9MW0113 (marketed as JUNMAIKANG in China) has received marketing approval in Indonesia. The approval marks a key milestone for Mabwell’s global expansion strategy and…
-
All In on Biosim AI with Simulations Plus
Overview: A New Era for Biosimilars The conversation around biosimilars is shifting from incremental improvements to rapid, AI-powered discovery and validation. In this era, Biosim AI—driven by advanced simulations and pharmacometric tools—offers a path to faster timelines, improved predictability, and greater confidence for regulators, manufacturers, and patients. A recent discussion hosted by TD Cowen Insights…
-
Mabwell Adalimumab Biosimilar Approved in Indonesia, Expands Southeast Asia Reach
Overview: Mabwell’s Adalimumab Biosimilar Gains Indonesian Marketing Approval Mabwell, a Shanghai-based biopharmaceutical company renowned for its integrated development-to-manufacturing approach, has secured marketing approval in Indonesia for its Adalimumab Injection 9MW0113, marketed as JUNMAIKANG in China. The green light from Indonesian regulators marks a significant milestone for Mabwell’s global expansion and for patients in Southeast Asia…
-
Alvotech’s Presentation Highlights at Morgan Stanley Conference
Introduction to Alvotech at the Morgan Stanley Conference Alvotech (ALVO), a prominent player in the biotechnology sector, recently made significant waves at the Morgan Stanley 23rd Annual Global Healthcare Conference. This gathering showcases influential companies in healthcare and biotechnology, presenting a platform for industry leaders to discuss innovations, challenges, and market outlooks. Thibault Boutherin, co-head…
-
Alvotech at Morgan Stanley Healthcare Conference: Key Insights
Introduction to Alvotech and the Conference Alvotech (ALVO) recently showcased its innovative capabilities at the Morgan Stanley 23rd Annual Global Healthcare Conference. This event brings together industry leaders, analysts, and investors to discuss trends and innovations in healthcare. Thibault Boutherin, co-head of the European Pharmaceutical team at Morgan Stanley, opened the session, setting the stage…
-
Alvotech at Morgan Stanley 23rd Annual Global Healthcare Conference
Introduction to Alvotech’s Presentation During the Morgan Stanley 23rd Annual Global Healthcare Conference, Alvotech (ALVO) presented key updates that highlighted its strategic direction and innovative approaches in the biopharmaceutical industry. Co-head of the European Pharmaceutical Equity Research, Thibault Boutherin, led the discussion, emphasizing the company’s commitment to developing high-quality biosimilars. Company Overview Alvotech specializes in…